Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for NCI-H1299 Cells (Lung Adenocarcinoma Cells, CRL-5803)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
High transfection efficacy in the presence of serum
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
- Download NCI-H1299 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for NCI-H1299 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCI-H1299 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-H1299 Cell Line:
Lung cancer is considered the leading cause of cancer death worldwide among both women and men. It mainly occurs in older people, with an average patient age of 70 years. Less than 2% of all diagnosed patients are younger than 45, per the American Cancer Society (ACS). Furthermore, it is the most preventable cancer, affecting smokers 15 to 30 times more often than people who do not smoke. Many lung cancer patients are resistant to current treatments, including chemotherapy and radiotherapy. The NCI-H1299 cell line was initially established from the lung cells of a 43-year-old Caucasian male patient with non-small cell lung cancer. These cells were derived from the lymph node metastatic site, and exhibit epithelial cell morphology. They lack expression of the p53 protein and have been known to synthesize peptide neuromedin B (NMB). NCI-H1299 are useful for studying lung cancer in humans. Altogen Biosystems offers transfection reagent kits for the NCI-H1299 cell line.
Cell line mutations:
Figure 1. GAPD mRNA levels were quantified using real-time PCR in the NCI-H1299 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in NCI-H1299 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into NCI-H1299 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient cellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6852)
- 1.5 ml (Catalog #6853)
- 1.5 ml CRISPR (Catalog #2176)
- 8.0 ml (Catalog #7066)